Literature DB >> 7712334

Long-term rat survival after malignant brain tumor regression by retroviral gene therapy.

M Izquierdo1, M Cortés, P de Felipe, V Martín, J Díez-Guerra, A Talavera, A Perez-Higueras.   

Abstract

Total regression of malignant brain tumors was observed in Wistar rats after retrovirus-mediated gene therapy. Tumors were induced by inoculation of C6 rat glioblastoma cells to a specific location in the rat brain and the tumors that developed were visualized by magnetic resonance imaging (MR). Retroviral vectors were constructed from a defective murine retrovirus to which the thymidine kinase (tk 1) gene from herpes simplex was added (HSV1tk). The vectors produced therapeutic viruses upon their introduction into retrovirus packaging cells. Delivery of the producer cells to the tumor mass and subsequent antiherpetic treatment eradicated the tumors completely, as observed using MRI. Some of the treated animals have been followed for over 8 months and show no signs of recurrence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712334

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

Review 1.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

5.  Parent phenotype and age dependence, on rat glioma tumor rejection.

Authors:  Alicia Gonzalez-Martin; Daniel Muñoz-Espin; Andrés M Alonso; Marta Izquierdo
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

Review 6.  Prodrug/drug sensitivity gene therapy: current status.

Authors:  W R Smythe
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.945

7.  Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

Authors:  Isabelle M Germano; Jennifer Fable; S Humayun Gultekin; Adam Silvers
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

8.  A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma.

Authors:  Ariane Söling; Christian Theiss; Stephanie Jungmichel; Nikolai G Rainov
Journal:  Genet Vaccines Ther       Date:  2004-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.